Anandamide , formally N-arachidonoylethanolamine , was first isolated in 1992 by Raphael Mechoulam and colleagues from porcine brain tissue. Its name derives from the Sanskrit ānanda, meaning bliss or joy. It is synthesised on demand from membrane phospholipid precursors, primarily via the enzyme N-acyl phosphatidylethanolamine-specific phospholipase D (NAPE-PLD), and is rapidly hydrolysed by fatty acid amide hydrolase (FAAH), giving it a comparatively short half-life relative to the phytocannabinoid THC.
AEA acts as a partial agonist at the CB1 receptor , distributed densely in the central nervous system; and at CB2 receptors, found predominantly in immune tissues. Its partial agonism at CB1 produces lower intrinsic efficacy than the full agonist THC, a distinction with pharmacological significance when researchers model receptor occupancy and downstream signalling. AEA also interacts with the transient receptor potential vanilloid type 1 (TRPV1) channel, classifying it as an endovanilloid as well as an endocannabinoid.
Several researchers have proposed a hypothesis, sometimes termed "endocannabinoid deficiency", suggesting that below-typical AEA tone may correlate with certain physiological states. This remains a working hypothesis; direct causal evidence in humans is limited, replication studies are ongoing, and no diagnostic standard for AEA deficiency is currently recognised by any Australian or international regulatory body.
In Australia, research involving manipulation of the endocannabinoid system, including AEA-related pathways, is conducted under standard institutional ethics frameworks. No therapeutic product targeting AEA synthesis or degradation is currently approved by the Therapeutic Goods Administration (TGA). Cannabinoid-related medicines on the Australian Register of Therapeutic Goods (ARTG) act via overlapping receptor pathways but are regulated as distinct chemical entities under the Poisons Standard.
Sources: